| Jeremy W Amps, MD | |
|
6701 Airport Blvd, Suite D146, Mobile, AL 36608 | |
| (251) 633-5155 | |
| (251) 633-5125 |
| Full Name | Jeremy W Amps |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 25 Years |
| Location | 6701 Airport Blvd, Mobile, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093810574 | NPI | - | NPPES |
| 2679481 | Medicaid | OH | |
| 515-43364 | Other | AL | BLUE CROSS BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 35086921 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Fairview Hospital | Cleveland, OH | Hospital |
| Cleveland Clinic | Cleveland, OH | Hospital |
| Lutheran Hospital | Cleveland, OH | Hospital |
| Medina Hospital | Medina, OH | Hospital |
| South Pointe Hospital | Warrensville heights, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cleveland Clinic Foundation | 1850203555 | 5690 |
News Archive
ImmunoCellular Therapeutics announced today that the U.S. Food and Drug Administration has granted orphan drug designation for ICT-107, the company's dendritic cell-based cancer vaccine candidate which targets glioblastoma multiforme. As a result of the orphan drug status, ImmunoCellular will be eligible to receive a number of benefits, including access to grant funding for clinical trials, tax credits, accelerated FDA approval and allowance for marketing exclusivity after drug approval for a period of up to seven years.
The scientists from the Washington University School of Medicine, St. Louis, say their research supports the 'cognitive reserve' hypothesis and individuals with levels of higher education levels score higher on cognitive tests despite having Alzheimer's disease.
pSivida Corp., a leader in the development of ophthalmic sustained release drug delivery products, today said it had received full payment of a $15 million note, including an additional $225,000 in accrued interest, from Alimera Sciences, Inc., pSivida's licensee developing Iluvien® for the treatment of diabetic macular edema (DME).
Researchers in Japan have warned that the Mu (B.1.621) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – appears to be highly resistant to neutralization by sera from convalescent or vaccinated individuals.
› Verified 6 days ago
| Entity Name | The Cleveland Clinic Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679525919 PECOS PAC ID: 1850203555 Enrollment ID: O20031103000049 |
News Archive
ImmunoCellular Therapeutics announced today that the U.S. Food and Drug Administration has granted orphan drug designation for ICT-107, the company's dendritic cell-based cancer vaccine candidate which targets glioblastoma multiforme. As a result of the orphan drug status, ImmunoCellular will be eligible to receive a number of benefits, including access to grant funding for clinical trials, tax credits, accelerated FDA approval and allowance for marketing exclusivity after drug approval for a period of up to seven years.
The scientists from the Washington University School of Medicine, St. Louis, say their research supports the 'cognitive reserve' hypothesis and individuals with levels of higher education levels score higher on cognitive tests despite having Alzheimer's disease.
pSivida Corp., a leader in the development of ophthalmic sustained release drug delivery products, today said it had received full payment of a $15 million note, including an additional $225,000 in accrued interest, from Alimera Sciences, Inc., pSivida's licensee developing Iluvien® for the treatment of diabetic macular edema (DME).
Researchers in Japan have warned that the Mu (B.1.621) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – appears to be highly resistant to neutralization by sera from convalescent or vaccinated individuals.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeremy W Amps, MD 6701 Airport Blvd, Suite D146, Mobile, AL 36608 Ph: (251) 633-5155 | Jeremy W Amps, MD 6701 Airport Blvd, Suite D146, Mobile, AL 36608 Ph: (251) 633-5155 |
News Archive
ImmunoCellular Therapeutics announced today that the U.S. Food and Drug Administration has granted orphan drug designation for ICT-107, the company's dendritic cell-based cancer vaccine candidate which targets glioblastoma multiforme. As a result of the orphan drug status, ImmunoCellular will be eligible to receive a number of benefits, including access to grant funding for clinical trials, tax credits, accelerated FDA approval and allowance for marketing exclusivity after drug approval for a period of up to seven years.
The scientists from the Washington University School of Medicine, St. Louis, say their research supports the 'cognitive reserve' hypothesis and individuals with levels of higher education levels score higher on cognitive tests despite having Alzheimer's disease.
pSivida Corp., a leader in the development of ophthalmic sustained release drug delivery products, today said it had received full payment of a $15 million note, including an additional $225,000 in accrued interest, from Alimera Sciences, Inc., pSivida's licensee developing Iluvien® for the treatment of diabetic macular edema (DME).
Researchers in Japan have warned that the Mu (B.1.621) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – appears to be highly resistant to neutralization by sera from convalescent or vaccinated individuals.
› Verified 6 days ago
Dr. Donald R Tyler, M. D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 3280 Dauphin St, Building A, Mobile, AL 36606 Phone: 251-450-3700 Fax: 251-662-3819 | |
Amber Shea Gordon, M.D. Neurological Surgery Medicare: May Accept Medicare Assignments Practice Location: 3 Mobile Infirmary Cir Ste 410, Mobile, AL 36607 Phone: 251-435-6850 Fax: 251-435-6859 | |
Dr. Shawn B Clark, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 6701 Airport Blvd Ste D146, Mobile, AL 36608 Phone: 251-287-2176 Fax: 251-287-2279 | |
Dr. James Ronald Hirsch, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 6701 Airport Blvd Ste D146, Mobile, AL 36608 Phone: 251-287-2176 Fax: 251-287-2279 | |
Andrew Kessler Romeo, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1601 Center St, Mobile, AL 36604 Phone: 251-660-5108 Fax: 251-660-5792 | |
Dr. Edward R Flotte, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 3280 Dauphin St, Building A, Mobile, AL 36606 Phone: 251-450-3700 Fax: 251-662-3819 |